CDSCO’s 2026 dental antibiotic, anesthetic and antiviral approvals list

The Central Drugs Standard Control Organisation has published its 2026 approvals for dental therapeutics, featuring antibiotic formulations (e.g., amoxicillin-clavulanate 625 mg TID for odontogenic infections), local anesthetics (e.g., 2% lidocaine with 1:100,000 epinephrine for infiltration and nerve blocks), and antivirals (e.g., acyclovir 400 mg TID for herpetic lesions). These products are approved for dental pain management, infection control and viral prophylaxis, now available nationwide in India; consult updated dosing guidelines per procedure.